Can Ischemia Modified Album Be Used as a Diagnostic Value in Acute Coronary Syndrome?

Research Article




Acute coronary syndrome, Ischemia modified albumin, Biomarker


Introduction: Acute coronary syndromes (ACS) are the main cause of mortality and morbidity worldwide. Appropriate management of patients presenting to emergency departments (ED) with suspected ACS depends on early detection of signs of cardiac ischemia.

Aim: In this study, we aimed to investigate the diagnostic value of ischemia modified albümin (IMA) in ACS.

Metho: The study included 169 patients admitted to the ED between October 2012 and April 2013 with chest pain. Albumin, troponin-T and IMA were measured in the patients. 21 patients were included in the Non–St-Segment Elevation Myocardial İnfarctions (NSTEMI) group and 49 patients were included in the unstable angina pectoris (UAP) group. The control group included 99 patients. At the end of the study, the parameters of the three groups were compared.

Results: The IMA level of NSTEMIgroup was higher than the control group (0.33±0.03, 0.24±0.04, p<0.001). Similarly, the IMA level of UAP group was higher than the control (0.29±0.011, 0.24±0.04 p<0.001). IMA and IMA/Albumin levels of the ACS group were also higher than the control group (0.30±0.029, 0.241±0.041 p<0.001).

Conclusion: IMA levels were higher in both NSTEMI group and UAP group compared to the control group in the early periods when other myocardial damage markers were negative in patients admitted to the ED with chest pain. This suggests that IMA level may play a more important role than troponin in risk assessment and determination of treatment strategy in patients admitted to the ED with suspected ACS in the early hours. 


Thupakula S, Nimmala SSR, Ravula H, et al. Emerging biomarkers for the detection of cardiovascular diseases. Egypt Heart J. 2022;74(1):77.

Boeddinghaus J, Nestelberger T, Koechlin L, et al. Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I [publishedcorrectionappears in J AmCollCardiol. 2020 Jun 16;75(23):3001]. J Am Coll Cardiol. 2020;75(10):1111-1124.

Muzyk P, Twerenbold R, Morawiec B, et al. Use of cardiactroponin in the early diagnosis of acute myocardial infarction. Kardiol Pol. 2020;78(11):1099-1106.

Kim SY, Lee JP, Shin WR, et al. Cardiac biomarkers and detection methods for myocardial infarction. Mol Cell Toxicol. 2022;18(4):443-455.

Eggers KM, Lindahl B. Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins. Curr CardiolRep. 2017;19(4):29.

Shevtsova A, Gordiienko I, Tkachenko V, Ushakova G. Ischemia-Modified Albumin: Originsand ClinicalImplications. Dis Markers. 2021;2021:9945424.

Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006;152(2):253-262.

Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J EmergMed. 2000 Nov;19(4):311-5

Zalenski RJ, McCarren M, Roberts R, et al. An evaluation of a chest pain diagnostic protocol to exclude acute cardiac ischemia in the emergency department. Arch InternMed. 1997;157(10):1085-1091.

Chaulin AM. The Metabolic Pathway of Cardiac Troponins Release: Mechanisms and Diagnostic Role. Cardiol Res. 2022;13(4):190-205

Hedges JR, Swanson JR, Heeter C, et al. Prospective assessment of presenting serum markers for cardiac risk stratification. Acad EmergMed. 1996;3(1):27-33.

Berezin AE, Berezin AA. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Oldand New Biomarkers. Dis Markers. 2020;2020:1215802.

Hönemann JN, Gerlach D, Hoffmann F, et al. Hypoxiaand Cardiac Function in Patients With Prior Myocardial Infarction. Circ Res. 2023;132(9):1165-1167.

Aladağ N, Asoğlu R, Ozdemir M, et al. Oxidants and antioxidants in myocardial infarction (MI): Investigation of ischemia modified albumin, malondialdehyde, super oxide dismutase and catalase in individuals diagnosed with ST elevated myocardial infarction (STEMI) andnon-STEMI (NSTEMI). J Med Biochem. 2021;40(3):286-294.

Shevtsova A, Gordiienko I, Tkachenko V,et al. Ischemia-Modified Albumin: Originsand Clinical Implications. Dis Markers. 2021;2021:9945424.

Bar –or D, Lau E, Rao N, et al. Reduction in the cobalt binding capacity of human albumin with myocardial ischemia. Ann EmergMed 1999;34 (4 suppl): S56

Mou H, Shao J, Zhang J, et al. Wang H. Ischemia-modified Albumin to Evaluate Short-term Prognostic of Patients with Acute Coronary Syndrome. J Coll Physicians Surg Pak. 2021;31(7):841-845.

Mangoni AA, Zinellu A. Serum Concentrations of Ischaemia-Modified Albumin in Acute Coronary Syndrome: A Systematic Reviewand Meta-Analysis. J Clin Med. 2022;11(14):4205.



How to Cite

İmre, G., & Kocas, C. (2024). Can Ischemia Modified Album Be Used as a Diagnostic Value in Acute Coronary Syndrome? Research Article. Acta Medica Ruha, 2(2), 86–91.



Research Articles